Summit Abstract books
- REG 2015 Rotterdam Summit (Rotterdam; January 2015): Meeting abstracts from the Respiratory Effectiveness Group 2015 Winter Summit – databases and registries around the world: maximizing the yield. Pragmatic and Observational Research. 2015; 6:13—38
- REG 2014 Inaugural Summit (June 2014): Abstracts from the Respiratory Effectiveness Group’s inaugural summit, June 2014. The Royal College of General Practitioners, London, 28–29 June 2014
Arch Supplement: Helping to Further the Science of Pragmatic Research, Annals of the American Thoracic Society, 20 February, 2014
- S83 The Arch Conference Declaration: Helping to Further the Science of Pragmatic Research
- Richard J. Martin, Alison M. Chisholm, and David Price
- S85 Respiratory Guidelines—Which Real World?
- Gary W. K. Wong, Marc Miravitlles, Alison Chisholm, and Jerry Krishnan
- S92 Complementing the Randomized Controlled Trial Evidence Base: Evolution Not Revolution
- David Price, Eric D. Bateman, Alison Chisholm, Nikolaos G. Papadopoulos, Sinthia Bosnic-Anticevich, Emilio Pizzichini, Elizabeth V. Hillyer, and A. Sonia Buist
- S99 Quality Standards for Real-World Research: Focus on Observational Database Studies of Comparative Effectiveness
- Nicolas Roche, Helen Reddel, Richard Martin, Guy Brusselle, Alberto Papi, Mike Thomas, Dirjke Postma, Vicky Thomas, Cynthia Rand, Alison Chisholm, and David Price; for the Respiratory Effectiveness Group
- S105 The “E” in Cost-Effectiveness Analyses: A Case Study of Omalizumab Efficacy and Effectiveness for Cost-Effectiveness Analysis Evidence
- Jonathan D. Campbell, R. Brett McQueen, and Andrew Briggs
- S112 Integrating Patients into Meaningful Real-World Research
- Susan J. Bartlett, Teresa Barnes, and R. Andrew McIvor
- S118 Phase IV Implementation Studies: The Forgotten Finale to the Complex Intervention Methodology Framework
- Hilary Pinnock, Eleni Epiphaniou, and Stephanie J. C. Taylor
Comment & Correspondence
- “Feasibility and Ethics”. Price D, Roche N, Martin Rj, Chisholm A. American Journal of Respiratory and Critical Care Medicine, 2013;188:1368-1369.
- Integrating real-life studies in the global therapeutic research framework. Roche N, Reddel HK, Agusti A, Bateman ED, Krishnan JA, Martin RJ, Papi A, Postma D, Thomas M, Brusselle G, Israel E, Rand C, Chisholm A, Price D. Lancet Respir Med, 2013;1(8):30–32.
- Letter to Editor: Differential Effects of Inhaled Corticosteroids in Smokers/Ex-Smokers and Nonsmokers with Asthma. Roche N, Postma D, Colice G, et al on behalf of the REG Small Airways Study Group (SASG). AJRCCM. 2015;191(160–163)
- Integrating Evidence for Managing Asthma in Patients Who Smoke. Price D, Bjermer L, Popov TA, Chisholm A. Allergy Asthma Immunol Res. 2014 March;6(2):114-120.
- Efficacy versus effectiveness trials — informing guidelines for asthma management. Price D, Hillyer E, van der Molen T. Curr Opin Allergy Clin Immunol. 2013; 13:50-7.
- Real-life Asthma Treatment Strategies: The missing piece of the jigsaw. Price D, Bjermer L, Haughney J, et al. Treatment Strategies – Respiratory. 2013;3(2):37–46
- InternationaL cross-sectIonAl and longItudinal assessment on aSthma cONtrol in European adult patients-the LIAISON study protocol. Braido F, Brusselle G, Ingrassia E, et al. BMC Pulmonary Medicine, 2013;13:18
- Detection of exacerbations in asthma based on electronic diary data: results from the 1-year prospective BIOAIR study. Kupczyk M, Haque S, Sterk PJ, et al. 2013. Thorax;68:611–618.
- Database studies in asthma pharmacoeconomics: uses, limitations and quality markers. Thomas M, Cleland J, Price D. Expert Opin. Pharmacother. 2003;4.
- Stakeholder priorities for comparative effectiveness research in chronic obstructive pulmonary disease: a workshop report. Krishnan J, Lindenauer PK, Au DH, et al on behalf of the CONCERT group. Am J Respir Crit Care Med.2013; 187:320-6.
MHRA guidance on devices – may apply to people carrying out non-interventional studies in Europe:
- MHRA Bulletin No. 17; safeguarding public health: Medical Devices and Medicinal Products
- MHRA Bulletin No. 10. Classification Rules (June 2011)
Diagnosis & Epidemiology
- FENO and AHR mannitol in patients referred to an out-of-hospital asthma clinic: a real-life study. J Asthma. 2014; Jan 23. Backer V, Sverrild A, Porsbjerg C.
- Feasibility and effectiveness of an Asthma/COPD service for primary care: a cross-sectional baseline description and longitudinal results Riemersma RA, Kocks JH, Piersma-Wichers MG, Sanderman R, van der Molen T. 2015. Primary Care Respiratory Medicine. 25; Article number: 14101
- Clinical and cost effectiveness of mobile phone supported self monitoring of asthma: multicentre randomised controlled trial. Ryan D, Pinnock H, Lee AJ. BMJ. 2012; 344: e1756.
- The value of self-report assessment of adherence, rhinitis and smoking in relation to asthma control. Clatworthy J, Price D, Ryan D, et al. PCRJ: 2009;18: 300-305
- Leukotriene antagonists as first-line or add-on asthma-controller therapy. Price D, Musgrave SD, Shepstone L, et al. NEJM. 2011;364(18):1695-707.
- Real-life comparison of beclometasone dipropionate as an extrafine- or larger-particle formulation for asthma. Price D, Thomas M, Haughney J, et al. Respiratory Medicine. 2013; 107: 987-1000
- Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone. Colice G, Martin RJ, Israel E, et al. J Allergy Clin Immunol. 2013 Apr 13. pii: S0091-6749(13)00314-X. doi: 10.1016/j.jaci.2013.02.008. [Epub ahead of print]
- Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation. Müller V, Gálffy G, Eszes N, et al. BMC Pulm Med. 2011; 11: 4
- Asthma control with extrafine-particle hydrofluoroalkane–beclometasone vs. large-particle chlorofluorocarbon–beclometasone: a real-world observational study. Barnes N, Price D,Colice G, et al. Clin Exp Allergy. 2011;41; 1521–1532.
- Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: A real-world observational study. Price D, Martin RJ, Barnes N, et al. J Allergy Clin Immunol. 2010; 126:511-518.e10.
- Observational study comparing intranasal mometasone furoate with oral antihistamines for rhinitis and asthma. Price D, Kemp L, Sims E, et al. PCRJ. 2010; 19:277–273.
- A UK-Based Cost-Utility Analysis of Indacaterol, A Once-Daily Maintenance Bronchodilator for Patients with COPD, Using Real World Evidence on Resource Use. Price D, Asukai Y, Ananthapavan J, Malcolm B, et al. Applied Health Economics Health Policy. 2013 Mar 26. [Epub ahead of print]
- Study on drug costs associated with COPD prescription medicine in Denmark. Jakobsen M, Anker N, Dollerup J, Paulsen PB, Lange P. Clin Respir J 2012; Nov 21. doi: 10.1111/crj.12010. [Epub ahead of print]
Reviews / Opinion
- Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper.Bousquet J, Schünemann HJ, Zuberbier T, et al. In collaboration with the WHO Collaborating Center of Asthma and Rhinitis (Montpellier).
- Preliminary Draft Methodology Report: “Our Questions, Our Decisions: Standards for Patient‐centered Outcomes Research” The Patient-Centered Outcomes Research Institute. 2012.
- An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations: Standardizing Endpoints for Clinical Asthma Trials and Clinical Practice. Reddel HK, Taylor DR, Bateman ED, et al on behalf of the American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. 2009. Am J Respir Crit Care Med. 180; 59–99.
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS) – Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. 2013. Value in Health.16: 231-250.
Methodologies and Outcomes
- Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? McDonald VM, Higgins I, Wood LG, Gibson PG. 2013. Thorax. 68:691–694
- Getting the Methods Right — The Foundation of Patient-Centered Outcomes Research. Gabriel SE, S-L T Normand. N Engl J Med. 2012; 367:787-79.
- Perspective Comparative Effectiveness: Asking The Right Questions, Choosing The Right Method. Teutsch SM, Berger ML, Weinstein MC. Health Aff (Millwood). 2005;24:128-32
- Asthma outcomes: Healthcare utilization and costs. Akinbami LJ, Sullivan SD, Campbell JD. JACI. 2012;129:S49-S64
- Asthma outcomes workshop: Overview. Busse WW, Morgan WJ, Taggart V. JACI. 2012;129(3): S1-S8
Calls for Action
- The Brussels Declaration: the need for change in asthma management. Holgate S, Bisgaard H, Bjermer L, et al. Eur Respir J. 2008;32:1433–42.
- A call for action: comparative effectiveness research in asthma. Krishnan JA, Schatz M, Apter AJ. J Allergy Clin Immunol. 2011;127:123–7.
- Reassessing the Evidence Hierarchy in Asthma: Evaluating Comparative Effectiveness.Price D, Chisholm A, van der Molen T. Curr Allergy Asthma Rep. 2011; 11:526–538.
- The importance of primary care research in the management of respiratory disease. Holgate S. Prim Care Respir J. 2012; 21(1): 1-16
- Harveian Oration. Sir Michael Rawlins, Chairman of the National Institute for Health and Clinical Excellence (NICE). Oct-2008 ed. London: Royal College of Physicians; 2008
- Comparative Effectiveness Research in Lung Diseases and Sleep Disorders. Lieu TA, Au D, Krishnan JA. Am J Respir Crit Care Med. 2011; 184: 848–856
- Inhaler devices for asthma: a call for action in a neglected field. Papi A, Haughney J, Virchow JC. Eur Respir J. 2011; 37: 982–985
- Device type and real-world effectiveness of asthma combination therapy: An observational study. Price D, Roche N, Virchow JC, et al. Respir Med. 2011;105:1457-66.
- Effectiveness of inhaler types for real-world asthma management: retrospective observational study using the GPRD. Price D, Haughney J, Sims E, et al. Journal of Asthma and Allergy. 2011:4 37–47
- Cost-effectiveness analysis of corticosteroid inhaler devices in primary care asthma management: A real world observational study. Kemp L, Haughney J, Barnes N, et al. ClinicoEconomics and Outcomes Research 2010:2 75–85
- Differences between clinical trials and postmarketing use. Martin K, Bégaud B, Latry P. Br J Clin Pharmacol. 2003; 57:86-92
- Guideline on safety and efficacy follow-up – risk management of advanced therapy medicinal products. European Medicines Agency. London, May 2008. Doc. Ref. EMEA/149995/2008